Retrospective analysis of clinical and molecular characteristics as prognostic factors in adult T-cell lymphoblastic lymphoma

  • 0Department of Hematology, Cancer Hospital Affiliated to Shanxi Medical University/Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences Taiyuan 030013, Shanxi, China.

|

|

Summary

This summary is machine-generated.

Adult T-cell lymphoblastic lymphoma (T-LBL) often presents with advanced disease and frequent mutations. Female sex, lack of complete response, and high LDH levels predict poor survival, guiding targeted therapy development.

Area Of Science

  • Hematology
  • Oncology
  • Molecular Biology

Background

  • Adult T-cell lymphoblastic lymphoma (T-LBL) is an aggressive hematologic malignancy.
  • Understanding its clinical and molecular landscape is crucial for improving patient outcomes.

Purpose Of The Study

  • To analyze clinical characteristics and molecular biomarkers of T-LBL.
  • To identify prognostic factors and evaluate chemotherapy efficacy.
  • To provide a basis for optimizing T-LBL treatment strategies.

Main Methods

  • Retrospective analysis of 89 adult T-LBL patients.
  • Collection of clinical data, treatment details, and mutational profiles.
  • Assessment of prognostic factors and comparison of two chemotherapy regimens.

Main Results

  • Most patients presented with advanced disease (stages III-IV), mediastinal invasion (70.80%), and B symptoms (66.30%).
  • NOTCH1 was the most frequent mutation, followed by PHF-6, JAK-1, JAK-3, IL-7R, and TP53.
  • Complete response rate was 51.69%; 3-year OS and PFS were 74.9% and 58.80%, respectively.
  • Independent predictors of poor overall survival included female sex, lack of complete response, and elevated LDH levels.

Conclusions

  • T-LBL exhibits frequent gene mutations in signaling pathways.
  • Mediastinal and extranodal involvement are prevalent and associated with poor prognosis in Chinese patients.
  • Combined clinical and molecular assessment improves prognostic stratification and aids targeted therapy development for high-risk T-LBL patients.